Last update 08 May 2025

ACE-232

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
CYP11A1
Action
inhibitors
Mechanism
CYP11A1 inhibitors(Cytochrome P450 11A1 inhibitors)
Therapeutic Areas
NeoplasmsUrogenital DiseasesEndocrinology and Metabolic Disease+ [1]
Active Indication
Adenocarcinoma of prostateMetastatic castration-resistant prostate cancerAdrenocortical Carcinoma
Inactive Indication-
Originator Organization
Acerand Therapeutics (Hong Kong) Ltd.
Active Organization
Acerand Therapeutics (Hong Kong) Ltd.Acerand Therapeutics (USA) Ltd.Acerand Therapeutics (Shanghai) Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with ACE-232
NCT06801236
/ Not yet recruitingPhase 1
A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC)
100 Clinical Results associated with ACE-232
Login to view more data
100 Translational Medicine associated with ACE-232
Login to view more data
100 Patents (Medical) associated with ACE-232
Login to view more data
100 Deals associated with ACE-232
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of prostatePhase 1
United States
Acerand Therapeutics (Hong Kong) Ltd.
01 May 2025
Metastatic castration-resistant prostate cancerPhase 1
United States
Acerand Therapeutics (Hong Kong) Ltd.
01 May 2025
Adrenocortical CarcinomaPreclinical
United States
Acerand Therapeutics (USA) Ltd.
30 Apr 2025
Adrenocortical CarcinomaPreclinical
China
Acerand Therapeutics (Shanghai) Co., Ltd.
30 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ACE-232 (AACR2025)
Not Applicable
AR ligand binding domain (LBD) mutations
-
rkcmjyejlo(hwejxlbcka) = ehkwrbypyw cqmsxnuyka (bvvsvvxsij )
Positive
30 Apr 2025
rkcmjyejlo(hwejxlbcka) = ilifwtoxpn cqmsxnuyka (bvvsvvxsij )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free